By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Detection and Eldan today announced an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in Israel and the Palestinian territories.

Financial and other terms of the deal were not disclosed. Eldan, based in Petach Tikva, Israel, is a diagnostic distributor that is part of the Neopharm Group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.